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Bio-Medical
A nanovector multistage system has
been created to overcome or bypass se-
quential barriers within the human
body, in order to deliver a therapeutic or
imaging agent to a specific location.
This innovation consists of a composi-
tion that includes two or more stages of
particles, such that smaller, later-stage
particles are contained in the larger,
early-stage particles (see figure). 
Such multistage compositions pro-
vide several advantages. An active agent,
such as a therapeutic agent or imaging
agent, is preferentially delivered and/or
localized to a particular target site in the
body of a subject. The multistage com-
position overcomes multiple biological
barriers in the body. The multistage
composition also allows for simultane-
ous delivery and localization at the same
or different target sites of multiple ac-
tive agents.
Following administration, an active
agent formulated conventionally, or in a
nanovector, encounters a number of bi-
ological barriers that adversely impact
the agent’s ability to reach an intended
target at a desired location. Because
these barriers are sequential, the
method for overcoming or bypassing
them has to be sequential as well. In this
innovation, each stage of the vehicle is
defined by a particle having a separate
intended function, which may be differ-
ent from an intended function of a par-
ticle of another stage. For example, a
particle of one stage is designed to target
a specific body site, which may be differ-
ent from a site targeted by a particle of
another stage.
A particle of each subsequent stage is
contained inside a particle of an imme-
diately preceding stage. A particle of
any particular stage may contain an ac-
tive agent, such as the therapeutic
agent or an imaging agent, intended
for use at this particular stage. The
number and type of stages in the multi-
stage delivery vehicle depends on sev-
eral parameters, including administra-
tion route and an intended final target
for the active agent. 
Sometimes, the particle of the first
stage is a micro or nano particle. Other
times, the first-stage particle has a charac-
teristic size of at least 500 µm, or at least
1 mm. Such a particle may be configured
to contain inside at least one micro or
nano particle, which, in turn, may con-
tain inside at least one particle of a
smaller size. The first stage particle is a
top-down fabricated particle, i.e., a parti-
cle prepared by top-down microfabrica-
tion or nanofabrication methods, such as
photolithography, electron beam lithog-
raphy, X-ray lithography, deep UV lithog-
raphy, or nanoprint lithography. A poten-
tial advantage of using the top-down
fabrication methods is that such methods
provide for a scaled-up production of par-
ticles that are uniform in dimensions.
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This method enables targeted delivery of therapeutic or imaging agents within a patient by
means of nested nanoparticles.
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In the Multistage Delivery Vehicle, the first-stage particle contains second-stage particles and an ad-
ditional agent such as an imaging or therapeutic agent. The second-stage particles may contain third-
stage particles. Targeting moieties such as antibodies attached to the first-stage particle facilitate lo-
calization at the selected body site. 
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